Clinical trial

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

NCT01761747

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2013-01-01

PhasePHASE2 / PHASE3

Study timeline

Study start (unknown)2013-01-01Date precision: month

Registry last updated2014-12-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancer, Head and Neck Cancerunresolved

Interventions

ponatinibDRUG · verified · RxNorm: ponatinib

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

Mapped research locations

BostonMassachusetts, United States4

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01761747 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.